Irvine Scientific introduces BalanCD HEK293 system for large-scale expression of proteins and viral vectors
New product range includes chemically-defined, serum-free media, to increase productivity of viral vectors and recombinant proteins in suspension cultures.
Irvine Scientific has introduced their BalanCD HEK293 System. The system includes a highly versatile series of chemically-defined media designed to increase productivity in a range of applications, rapidly delivering high yields of viral vectors and recombinant proteins.
BalanCD HEK293 System is fully scalable, and supports small to industrial scale batch sizes. Utilizing human embryonic kidney (HEK293) cells, the system supports applications including viral vector production for gene therapy, transient gene expression and recombinant protein production in suspension-adapted HEK293 cells.
Central to the new system’s versatility, scalability, and process efficiency is BalanCD HEK293, a bi-functional medium that supports both growth and transfection in multiple 293 cell lines, which means that there is no need to change media before and after transfection. This is complemented by BalanCD HEK293 Feed, designed to support high density cell growth to maximize production of recombinant proteins. Anti-Clumping Supplement further increases productivity by preventing the natural tendency of HEK293 to aggregate, thereby improving growth.
“Gene therapy is at the forefront of new medical therapies, but the ability to reliably produce viral vectors at industrial scale has been a challenge,” explained Dr Jessie Ni, Chief Scientific Officer at Irvine Scientific. “Our goal is to provide a reproducible solution to attaining high yields of viral vectors using a chemically-defined, suspension-cell-based platform that will help scientists further their ability to provide innovative treatments. Additionally, we designed the BalanCD HEK293 System to provide unmatched flexibility as well as performance to scientists working with 293 cell lines for other applications such as transient protein expression.”
To save time and cost in downstream processing, and to help meet regulatory requirements, BalanCD HEK293 growth and feed media are chemically-defined and animal component-free. Anti-Clumping Supplement is animal-component-free and enzyme-free. All products are manufactured in state-of-the-art cGMP facilities using strict raw material controls. To further facilitate regulatory compliance, Drug Master Files have been filed with the FDA.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance